Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-03-15
1997-07-22
Killos, Paul J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3800
Patent
active
056503962
ABSTRACT:
Methods for modulating the expression of inflammatory cytokines in the central nervous system comprising administering an effective amount of TGF-.beta. are disclosed. The methods include suppressing pro-inflammatory cytokines in the central nervous system by administering an effective amount of TGF-.beta. and inducing anti-inflammatory cytokines in the central nervous system by administering an effective amount of TGF-.beta..
REFERENCES:
Beutler et al., "The biology of cachectin/TNF-A primary mediator of the host response" Ann. Rev. Immunol. (1989) 7:625-655.
Selmaj et al., "Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro" Ann. Neurol. Assoc. (1988) 23:339-346.
Robbins et al., "Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes" J. Immunol. (1987) 139:2593-2597.
Raine, "Biology of disease: Analysis of autoimmune demyelination: Its impact upon multiple sclerosis" Lab. Invest. (1984) 50:608-635.
Selmaj, "Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor" J. Immunol. (1990) 144:129-135.
Panek et al., "Tumor necrosis factor .alpha. response elements in the HLA-DRA promoter: Identification of a tumor necrosis factor .alpha.-induced DNA-protein complex in astrocytes" Proc. Natl. Acad. Sci. USA (1992) 89:11518-11522.
Benveniste, "Inflammatory cytokines within the central nervous systems: sources, function, and mechanism of action" Am. J. Physiol.: Cell Physiol. (1992) 263:32:C1-C16.
Hofman, "Tumor necrosis factor identified in multiple sclerosis brain" J. Exp. Med. (1989) 170:607-612.
Selmaj, "Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions" J. Clin. Invest. (1991) 87:949-954.
Sharief et al., "Association between tumor necrosis factor-.alpha. and disease progression in patients with multiple sclerosis" N. Eng. J. Med. (1991) 325:467-472.
Sharief et al., "Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-.alpha. and blood-brain barrier damage" J. Neuroimmunol. (1993) 43:15-21.
Ruddle et al., "An antibody to lymphotoxin and tumor necrosis factor prevents transfer to experimental allergic encephalomyelitis" J. Exp. Med. (1990) 172:1193-1200.
Selmaj et al., "Anti-tumor necrosis factor therapy abrogates autoimmune demyelination" Ann. Neurol. (1991) 30:694-700.
Chung et al., "Tumor necrosis factor-.alpha. production by astrocytes: Induction by lipopolysaccharide, IFN-.gamma. and IL-1.beta." J. Immunol. (1990) 144:2999-3007.
Lieberman et al., "Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus" Proc. Natl. Acad. Sci. USA (1989) 86:6348-6352.
Chung et al., "Role of protein kinase C activity in tumor necrosis factor-.alpha. gene expression: Involvement at the transcriptional level" J. Immunol. (1992) 149:3894-3902.
Lieberman et al., "Protein kinase regulates tumor necrosis factor mRNA stability in virus-stimulated astrocytes" J. Exp. Med. (1990) 172:989-992.
Lieberman et al., "Poly(A) removal is the kinase-regulated step in tumor necrosis factor mRNA decay" J. Biol. Chem. (1992) 267:2123-2126.
Benveniste et al., "Intracellular second messengers involved in both induction and inhibition of TNF-.alpha. expression by astrocytes" J. Immunol. (1993) 150:245A.
Fisher et al., "Role of tyrosine kinase signalling in newcastle disease virus (NDV) mediated TNF-.alpha. gene activation in astrocytes" J. Immunol. (1993) 150:295A.
Frei et al., "On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases" Eur. J. Immunol. (1993) 19:689-694.
Norris et al., "Interleukin-6 production by astrocytes: Induction by the neurotransmitter norepinephrine". J. Neuroimmunol. (1993) 45:137-146.
Norris et al., "Signal transduction pathways mediating astrocyte IL-6 induction by IL-1.beta. and tumor necrosis factor-.alpha." J. Immunol. (1994) 152:841-850.
Hirano et al., "Biological and clinical aspects of interleukin 6" Immunology Today (1990) 11:443-449.
Aderka et al., "IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice" J. Immunol. (1989) 143:3517-3523.
Merrill, "Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome" J. Immunother. (1992) 12:167-170.
Massague, "The transforming growth factor-.beta. family" Annu. Rev. Cell. Biol. (1990) 6:597-641.
da Cunha et al., "Glial cell-specific mechanisms of TGF-.beta.1 induction by IL-1 in cerebral cortex" J. Neuroimmunol. (1993) 42:71-86.
Morganti-Kossmann et al., "Autocrine and paracrine regulation of astrocyte function by transforming growth factor-.beta." J. Neuroimmunol. (1992) 39:163-174.
Suzumura et al., "Transforming growth factor-.beta. suppresses activation and proliferation of microglia in vitro" J. Immunol. (1993) 151:2150-2158.
Schluesener, "Transforming growth factors type .beta.1 and .beta.2 suppress rat astrocyte autoantigen presentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by interferon-.gamma. and tumor necrosis factor-.alpha." J. Neuroimmunol. (1990) 27:41-47.
Lindholm et al., "Transforming growth factor-.beta.1 in the rat brain: increase after injury and inhibition of astrocyte proliferation" J. Cell Biol. (1992) 117:395-400.
Barnum et al., "Transforming growth factor-.beta.1 inhibits inflammatory cytokine-induced C3 gene expression in astrocytes" J. Immunol. (1994) 152:765-773.
Miller, "Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor .beta. after antigen-specific triggering" Proc. Natl. Acad. Sci. USA (1992) 89:421-425.
Johns et al., "Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-.beta.1" J. Immunol. (1991) 147:1792-1796.
Kuruvilla, "Protective effect of transforming growth factor .beta..sub.1 on experimental autoimmune diseases in mice" Proc. Natl. Acad. Sci. USA (1991) 88:2918-2921.
Racke et al., "Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-.beta.1" J. Immunol. (1991) 146:3012-3017.
Khoury et al., "Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalo-myelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor .beta., interleukin 4, and prostaglandin E expression in the brain" J. Exp. Med. (1992) 176:1355-1364.
Santambrogio et al., "Studies on the mechanisms by which transforming growth factor-.beta. (TGF-.beta.) protects against allergic encephalomyelitis: Antagonism between TGF-.beta. and tumor necrosis factor" J. Immunol. (1993) 151:1116-1127.
Nesbitt et al., "Differential regulation of interleukin-6 receptor and gp130 gene expression in rat hepatocytes" Mol. Biol. of the Cell (1992) 3:103-112.
Bogdan et al., "Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-.beta. and interleukin-10". J. Biol. Chem. (1992) 267:23301-23308.
Dubois et al., "Transforming growth factor .beta. is a potent inhibitor of interleukin 1 (IL-1) receptor expression: Proposed mechanism of inhibition of IL-1 action" J. Exp. Med. (1990) 172:737-744.
Pinson et al., "Regulation by transforming growth factor-.beta.1 of expression and function of the receptor for IFN-.gamma. on mouse macrophages" J. Immunol. (1992) 149:2028-2034.
McGee et al., "Transforming growth factor-.beta. and IL-1.beta. act in synergy to enhance IL-6 secretion by the intestinal epithelial cell line, IEC-6" J. Immunol. (1993) 151:970-978.
Elias et al., "Transforming growth factor-.beta. regulation of IL-6 production by unstimulated and IL-1 stimulated human fibroblasts" J. Immunol. (1991) 146:3437-3443.
Tanabe et al., "Genomic structure of the murine IL-6 ge
Benveniste Etty N.
Carlino Joseph A.
Celtrix Pharmaceuticals Inc.
Killos Paul J.
LandOfFree
Methods of modulating inflammatory cytokines in the CNS using TG does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of modulating inflammatory cytokines in the CNS using TG, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating inflammatory cytokines in the CNS using TG will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1560052